tDCS: Transcranial Direct Current Stimulation as Treatment for Auditory Hallucinations

Sponsor
Iris Sommer (Other)
Overall Status
Unknown status
CT.gov ID
NCT01977521
Collaborator
(none)
62
1
2
46.1
1.3

Study Details

Study Description

Brief Summary

The present study aims to examine the efficacy of transcranial direct current stimulation on the severity of auditory hallucinations.

Condition or Disease Intervention/Treatment Phase
  • Device: Eldith DC Stimulator stimulation
  • Device: Eldith DC Stimulator sham stimulation
N/A

Detailed Description

Rationale: Auditory hallucinations (AH) are a symptom of several psychiatric disorders, such as schizophrenia. In the majority of patients, these AH respond well to antipsychotic medication. Yet, a significant minority continues to experience frequent AH despite optimal pharmacotherapy and AH severely decrease quality of life in these patients. The number of alternative treatment options for this medication resistant group is currently low and most of them focus on coping with the hallucinations. Transcranial direct current stimulation (tDCS), in contrast, is a safe, non-invasive technique that is able to directly influence cortical excitability through the application of very low electric currents. This technique has only a few transient side-effects and is cheap and portable. To date, only one randomized controlled trial has been published, suggesting high efficacy of tDCS for the treatment of medication-resistant AH in a relatively small sample. We aim to replicate and extend these findings by investigating the efficacy of this technique in a larger sample.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
62 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Transcranial Direct Current Stimulation as Treatment for Auditory Hallucinations A Sham-controlled Trial
Study Start Date :
Apr 1, 2014
Anticipated Primary Completion Date :
Feb 1, 2018
Anticipated Study Completion Date :
Feb 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Treatment

transcranial direct current stimulation (2mA)

Device: Eldith DC Stimulator stimulation
The anodal electrode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex and the cathodal electrode located over a point midway between T3 and P3 (left temporo-parietal junction). Stimulation will consist of 2 mA for 20 minutes per session.

Sham Comparator: Sham

Sham stimulation

Device: Eldith DC Stimulator sham stimulation
The anodal electrode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex and the cathodal electrode located over a point midway between T3 and P3 (left temporo-parietal junction). In the sham condition, after 40 seconds of real stimulation (2 mA), only a small current pulse will occur every 550 msec (110 mA over 15 msec) through the remainder of the 20-minute period.

Outcome Measures

Primary Outcome Measures

  1. Total score of the Auditory Hallucination Rating Scale (AHRS) questionnaire [4 years]

    The primary outcome is the change in the severity of the hallucinations before and after the treatment, as experienced by the participant, measured with the Auditory Hallucination Rating Scale (AHRS)

Secondary Outcome Measures

  1. Changes in severity of hallucinations as assessed by the hallucination change scale (HCS)questionnaire [4 years]

  2. Changes of positive, negative and disorganized symptomatology as assessed by the positive and negative syndrome scale (PANSS) [4 years]

  3. Severity of psychotic symptoms will be measured by the questionnaire for psychotic symptoms (QPS) [4 years]

  4. Prior expectations regarding the efficacy of the treatment of the participants [4 years]

  5. Strength of the motor threshold as assessed using TMS [4 years]

  6. The presence and severity of side-effects will be monitored using the tDCS adverse effects questionnaire [4 years]

  7. Interference score on the Stroop task [4 years]

  8. Score on the Trailmaking test A and B [4 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age over 18.

  • Frequent auditory hallucinations (at least 5 times a week).

  • Patients are on a stable dose of antipsychotic medication (which can also be zero) for at least 2 weeks

  • Mentally competent for informed consent.

  • Provided informed consent.

Exclusion Criteria:
  • Metal objects in or around the head that cannot be removed (i.e. cochlear implant, surgical clips, piercing)

  • History of seizures, or a history of seizures in first-degree relatives.

  • History of eye trauma with a metal object or professional metal workers

  • History of brain surgery, brain infarction, head trauma, cerebrovascular accident, broken skull, brain tumour, heart disease, cardiac pacemaker.

  • Skin disease on the scalp on the position of the tDCS electrodes

  • Coercive treatment based on a judicial ruling

  • Pregnancy in female patients

Contacts and Locations

Locations

Site City State Country Postal Code
1 UMC Utrecht Netherlands 3584 CX

Sponsors and Collaborators

  • Iris Sommer

Investigators

  • Principal Investigator: Iris Sommer, PhD, UMC Utrecht

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Iris Sommer, Professor, Psychiatrist, UMC Utrecht
ClinicalTrials.gov Identifier:
NCT01977521
Other Study ID Numbers:
  • tDCS_UMC
First Posted:
Nov 6, 2013
Last Update Posted:
May 3, 2017
Last Verified:
May 1, 2017

Study Results

No Results Posted as of May 3, 2017